We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire NEW YORK, May 2, 2024 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK, April 29, 2024 NEW YORK, April 29, 2024...
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK, April 8, 2024 NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid...
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 26, 2024 Lucid's quarterly revenue increased 33 percent sequentially Launched...
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 25, 2024 Quarterly EsoGuard® revenue increased 33...
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire NEW YORK, March 21...
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference PR Newswire NEW YORK, March 20, 2024 Lucid and collaborators will present data on...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.2225 | 32.7205882353 | 0.68 | 0.99 | 0.6301 | 281159 | 0.81184686 | CS |
| 4 | -0.0075 | -0.824175824176 | 0.91 | 0.99 | 0.6301 | 197280 | 0.81230843 | CS |
| 12 | -0.4175 | -31.6287878788 | 1.32 | 1.4 | 0.6301 | 199572 | 0.99812739 | CS |
| 26 | -0.3875 | -30.0387596899 | 1.29 | 1.58 | 0.6301 | 116219 | 1.07288938 | CS |
| 52 | -0.5375 | -37.3263888889 | 1.44 | 1.85 | 0.6301 | 81938 | 1.18584977 | CS |
| 156 | -11.8475 | -92.9215686275 | 12.75 | 13.5 | 0.6301 | 120929 | 3.58696021 | CS |
| 260 | -11.8475 | -92.9215686275 | 12.75 | 13.5 | 0.6301 | 120929 | 3.58696021 | CS |
Monksdream
2 months ago
Monksdream
7 months ago
ErnieBilco
2 years ago
makinezmoney
2 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
